Tocotrienol Stabilization via Metallo-protein Chelation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Tocotrienols (T3) and their derivatives are unstable and sensitive to environmental factors, leading to short shelf life and reduced bioavailability, limiting their effectiveness in therapeutic applications due to degradation by metals like iron, copper, and zinc, and poor intestinal absorption.
Innovation Solution
Stabilization of T3 compounds using metallo-proteins such as lactoferrin, transferrin, ceruloplasmin, and metallo-thionein, which enhance chemical stability and bioavailability by blocking metal antagonists and facilitating intestinal transport.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If tocotrienols are used in therapeutic applications, then they can treat conditions like hyperlipidemia and atherosclerosis, but they degrade due to metal catalysts leading to short shelf life
Solution Approach 1:
The patent introduces metal chelators as intermediary substances that bind to metal ions (iron, copper, zinc) in the formulation, preventing these metals from catalyzing tocotrienol degradation. The chelators act as mediators between the tocotrienols and the metal contaminants, sequestering the metals in stable complexes that cannot promote oxidation reactions, thereby extending shelf life while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent converts the harmful effect of metal ions (which cause degradation) into a beneficial outcome by using chelators to deliberately bind these metals. The metals themselves are not removed but are transformed from harmful catalysts into harmless, sequestered complexes through chelation, allowing the tocotrienols to remain stable throughout their shelf life while retaining their therapeutic properties.
2Reliability
If tocotrienols are administered therapeutically, then they can lower cholesterol levels, but they have poor intestinal absorption and reduced bioavailability
Solution Approach 1:
The patent employs metal chelators as intermediary compounds that improve the physicochemical properties of tocotrienols, enhancing their solubility and stability in the gastrointestinal environment. The chelated tocotrienol complexes are more readily absorbed by intestinal cells compared to free tocotrienols, acting as mediators that facilitate the transition from poor absorption to improved bioavailability while maintaining the cholesterol-lowering therapeutic effect.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of T3 with metallo-proteins increases the stability and bioavailability of T3, effectively reducing serum cholesterol levels and improving therapeutic outcomes for conditions like hyperlipidemia and atherosclerosis.
Implementation Method 1
T3 and T3-like compounds stabilized with metallo-proteins... blocking metal antagonists
Implementation Method 2
facilitating intestinal transport
Data Source
AI summary
Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. Addition of a non-protein-type metal chelator provided further improvement in the action of the bio-functional activity of T3. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.